ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INO Inovio Pharmaceuticals Inc New

11.00
0.04 (0.36%)
25 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inovio Pharmaceuticals Inc New NASDAQ:INO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.04 0.36% 11.00 10.80 11.30 11.18 10.801 10.96 222,504 01:00:00

INOVIO to Present at the 2023 Jefferies Healthcare Conference

25/05/2023 1:00pm

PR Newswire (US)


Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Inovio Pharmaceuticals Charts.

PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.

2023 Jefferies Healthcare Conference
Date: Friday, June 9, 2023
Time: 8:00 AM ET
Format: Fireside Chat

During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-the-2023-jefferies-healthcare-conference-301834353.html

SOURCE INOVIO Pharmaceuticals, Inc.

Copyright 2023 PR Newswire

1 Year Inovio Pharmaceuticals Chart

1 Year Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock